<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:department>Inst of Pharmacy and Biomedical Sci</gtr:department><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7DDA3121-B4B2-43AC-AB43-9E76BEF26D1B"><gtr:id>7DDA3121-B4B2-43AC-AB43-9E76BEF26D1B</gtr:id><gtr:name>Mettler-Toledo Ltd</gtr:name><gtr:address><gtr:line1>64 Boston Road</gtr:line1><gtr:line2>Beaumont Leys</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE4 1AW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3104C5FA-18F6-4739-9FEC-FE4E58046127"><gtr:id>3104C5FA-18F6-4739-9FEC-FE4E58046127</gtr:id><gtr:name>AB Sugar (British Sugar Group)</gtr:name><gtr:address><gtr:line1>Sugar Way</gtr:line1><gtr:postCode>PE2 9AY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11C45689-C208-49DC-A95B-1B971827AEB3"><gtr:id>11C45689-C208-49DC-A95B-1B971827AEB3</gtr:id><gtr:name>Merck &amp; Co Inc</gtr:name><gtr:address><gtr:line1>Merck &amp; Co Inc</gtr:line1><gtr:line2>One Merck Drive</gtr:line2><gtr:line4>Whitehouse Station</gtr:line4><gtr:line5>NJ 08889-0100</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7989ED9B-5D1A-4201-A8BD-AB943285E55A"><gtr:id>7989ED9B-5D1A-4201-A8BD-AB943285E55A</gtr:id><gtr:name>National Physical Laboratory NPL</gtr:name><gtr:address><gtr:line1>National Physical Laboratory</gtr:line1><gtr:line4>Teddington</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>TW11 0LW</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F1E0A44-0778-4833-9405-0D5C2309D672"><gtr:id>4F1E0A44-0778-4833-9405-0D5C2309D672</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>Wilton Centre
Wilton</gtr:line1><gtr:city>Redcar</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52ADA13E-D63F-4D68-9A7D-B076D1DEAD5F"><gtr:id>52ADA13E-D63F-4D68-9A7D-B076D1DEAD5F</gtr:id><gtr:name>Mars Chocolate UK Ltd</gtr:name><gtr:address><gtr:line1>3D Dundee Road</gtr:line1><gtr:line2>Slough</gtr:line2><gtr:line3>Berkshire</gtr:line3><gtr:postCode>SL1 4LG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E9C787-1A64-4626-9702-3BA402E2D8CB"><gtr:id>C1E9C787-1A64-4626-9702-3BA402E2D8CB</gtr:id><gtr:name>Siemens Public Limited Company</gtr:name><gtr:address><gtr:line1>Sir Williams Siemens House</gtr:line1><gtr:line2>Princess Road</gtr:line2><gtr:postCode>M20 2UR</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/34E294E0-B661-4E1D-AFE5-DDF12D222057"><gtr:id>34E294E0-B661-4E1D-AFE5-DDF12D222057</gtr:id><gtr:name>DEM Solutions Limited</gtr:name><gtr:address><gtr:line1>49 Queen Street</gtr:line1><gtr:postCode>EH2 3NH</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51FBF84E-E90B-42F7-9550-81D65E053C16"><gtr:id>51FBF84E-E90B-42F7-9550-81D65E053C16</gtr:id><gtr:name>Malvern Instruments Ltd</gtr:name><gtr:address><gtr:line1>Enigma Business Park</gtr:line1><gtr:line2>Grovewood Road</gtr:line2><gtr:line4>Malvern</gtr:line4><gtr:line5>Worcestershire</gtr:line5><gtr:postCode>WR14 1XZ</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FA3B38B-3505-4F02-97C6-75FB9DF3AF2E"><gtr:id>1FA3B38B-3505-4F02-97C6-75FB9DF3AF2E</gtr:id><gtr:name>Takeda Pharmaceutical International Co,</gtr:name><gtr:address><gtr:line1>40 Landsdowne Street</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84EF1575-C804-40B1-8A3C-2E6CD95A8E41"><gtr:id>84EF1575-C804-40B1-8A3C-2E6CD95A8E41</gtr:id><gtr:name>Croda International Plc</gtr:name><gtr:address><gtr:line1>Cowick Hall</gtr:line1><gtr:line2>Snaith</gtr:line2><gtr:postCode>DN14 9AA</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/14E0E5BF-E946-4743-B7CE-0B743670EF9B"><gtr:id>14E0E5BF-E946-4743-B7CE-0B743670EF9B</gtr:id><gtr:name>Perceptive Engineering Limited</gtr:name><gtr:address><gtr:line1>Daresbury Innovation Centre</gtr:line1><gtr:line2>Keckwick Lane</gtr:line2><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1B60A73-0446-41C6-86F2-DF3F4E4815D9"><gtr:id>D1B60A73-0446-41C6-86F2-DF3F4E4815D9</gtr:id><gtr:name>Alconbury Weston Ltd</gtr:name><gtr:address><gtr:line1>Unit D3</gtr:line1><gtr:line2>Fenton Trade Park</gtr:line2><gtr:line3>Dewsbury Road Fenton</gtr:line3><gtr:postCode>ST4 2TE</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FA1B7BD-8462-415C-AA15-F11F5B1EF569"><gtr:id>0FA1B7BD-8462-415C-AA15-F11F5B1EF569</gtr:id><gtr:name>Booth Welsh</gtr:name><gtr:address><gtr:line1>3 Riverside Way</gtr:line1><gtr:postCode>KA11 5DJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20F14D02-2072-405B-83DB-36C094443CA8"><gtr:id>20F14D02-2072-405B-83DB-36C094443CA8</gtr:id><gtr:name>BRITEST Ltd</gtr:name><gtr:address><gtr:line1>Sci-Tech Daresbury</gtr:line1><gtr:line2>Keckwick Lane</gtr:line2><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B7CEF45F-CB73-42A5-8EE4-AB8057164674"><gtr:id>B7CEF45F-CB73-42A5-8EE4-AB8057164674</gtr:id><gtr:name>AM Technology</gtr:name><gtr:address><gtr:line1>The Heath Business &amp; Technical Park</gtr:line1><gtr:postCode>WA7 4QX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52DF3725-6BDC-4A88-A5FD-8E28FAB531BA"><gtr:id>52DF3725-6BDC-4A88-A5FD-8E28FAB531BA</gtr:id><gtr:name>FUJIFILM Imaging colorants Limited</gtr:name><gtr:address><gtr:line1>EARLS ROAD GRANGEMOUTH</gtr:line1><gtr:line4>STIRLINGSHIRE</gtr:line4><gtr:line5>SCOTLAND</gtr:line5><gtr:postCode>FK3 8XG</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A3A1CFB-E505-448B-9886-1FA6C1828CB8"><gtr:id>5A3A1CFB-E505-448B-9886-1FA6C1828CB8</gtr:id><gtr:name>Hovione (International)</gtr:name><gtr:address><gtr:line1>Sete Casas</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07883787-C252-44BB-81D1-81AECF29A9A1"><gtr:id>07883787-C252-44BB-81D1-81AECF29A9A1</gtr:id><gtr:name>Diamond Light Source</gtr:name><gtr:address><gtr:line1>Diamond House</gtr:line1><gtr:line2>Harwell Science and Innovation Camp</gtr:line2><gtr:line3>Didcot</gtr:line3><gtr:line4>Oxfordshire</gtr:line4><gtr:postCode>OX11 0DE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84EC36D9-AAC8-496A-B69B-F9DE2213B154"><gtr:id>84EC36D9-AAC8-496A-B69B-F9DE2213B154</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/519097F5-30C9-4B4F-B871-BBCD70AFCDC0"><gtr:id>519097F5-30C9-4B4F-B871-BBCD70AFCDC0</gtr:id><gtr:name>Clairet Scientific Ltd</gtr:name><gtr:address><gtr:line1>Boarden Close</gtr:line1><gtr:line2>Moulten Park Ind. Est.</gtr:line2><gtr:line3>Nothampton</gtr:line3><gtr:postCode>NN3 6AP</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBD8FC73-90C8-40C5-AAD9-A3C601B4DDF7"><gtr:id>DBD8FC73-90C8-40C5-AAD9-A3C601B4DDF7</gtr:id><gtr:name>Syngenta Ltd</gtr:name><gtr:address><gtr:line1>Environmental Safety</gtr:line1><gtr:line2>Jealotts Hill International Centre</gtr:line2><gtr:line4>Bracknell</gtr:line4><gtr:postCode>RG42 6EY</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C004649F-C1AC-4A9A-9C89-5B687469187D"><gtr:id>C004649F-C1AC-4A9A-9C89-5B687469187D</gtr:id><gtr:name>Blacktrace Holdings Limited</gtr:name><gtr:address><gtr:line1>Blacktrace Holdings Limited</gtr:line1><gtr:line2>Unit 1, Anglian Business Park</gtr:line2><gtr:line3>Orchard Road</gtr:line3><gtr:postCode>SG8 5TW</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/508C6217-C9D5-4B17-9D69-9F2F6731A0E4"><gtr:id>508C6217-C9D5-4B17-9D69-9F2F6731A0E4</gtr:id><gtr:name>Infineum UK Ltd</gtr:name><gtr:address><gtr:line1>PO Box 1</gtr:line1><gtr:line2>Milton Hill</gtr:line2><gtr:line3>Abingdon</gtr:line3><gtr:line4>Oxfordshire</gtr:line4><gtr:postCode>OX13 6BB</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C74251A-D7CF-4A25-9DFA-9AFAF577A6E4"><gtr:id>2C74251A-D7CF-4A25-9DFA-9AFAF577A6E4</gtr:id><gtr:name>Robinson Brothers Ltd</gtr:name><gtr:address><gtr:line1>Phoenix Street</gtr:line1><gtr:line4>West Bromwich</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>B70 0AH</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8ACF7AFE-1EB4-454D-8752-6970A7165B17"><gtr:id>8ACF7AFE-1EB4-454D-8752-6970A7165B17</gtr:id><gtr:name>Technobis Crystallization Systems</gtr:name><gtr:address><gtr:line1>Pyrietstraat 2</gtr:line1><gtr:line2>1812 SC Alkmaar</gtr:line2><gtr:postCode>1812 SC</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70185893-70E7-4938-90EA-322699255548"><gtr:id>70185893-70E7-4938-90EA-322699255548</gtr:id><gtr:name>Solid Form Solutions</gtr:name><gtr:address><gtr:line1>Roslin Biocentre</gtr:line1><gtr:line2>Wallace Building</gtr:line2><gtr:line3>Roslin</gtr:line3><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D4A0A33-D91C-44C3-8775-20E0B57650A8"><gtr:id>2D4A0A33-D91C-44C3-8775-20E0B57650A8</gtr:id><gtr:name>Bayer Pharma AG</gtr:name><gtr:address><gtr:line1>BPH-DD-CPD</gtr:line1><gtr:postCode>42096</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6FA4BF9D-D59F-4139-B0E6-10180D9ABAB3"><gtr:id>6FA4BF9D-D59F-4139-B0E6-10180D9ABAB3</gtr:id><gtr:name>Sirius Analytical Instrumentation Ltd</gtr:name><gtr:address><gtr:line1>Forest Row Business Park</gtr:line1><gtr:line2>Station Road</gtr:line2><gtr:postCode>RH18 5DW</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DCFC0BC4-F77B-4CEC-A612-ADA0EEA7EC45"><gtr:id>DCFC0BC4-F77B-4CEC-A612-ADA0EEA7EC45</gtr:id><gtr:name>Knowledge Transfer Network</gtr:name><gtr:address><gtr:line1>Bailey House</gtr:line1><gtr:line2>4-10 Barttelot Road</gtr:line2><gtr:postCode>RH12 1DQ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D588731-4D4C-4EE4-B0DC-B2A4E390FB80"><gtr:id>2D588731-4D4C-4EE4-B0DC-B2A4E390FB80</gtr:id><gtr:name>NiTech Solutions Ltd</gtr:name><gtr:address><gtr:line1>Scottish Enterprise Technology Park.</gtr:line1><gtr:line2>Newton Building, Rankine Avenue</gtr:line2><gtr:line3>East Kilbride</gtr:line3><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G75 0QF</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2BB30ED9-D4C7-4BF2-AF15-B9F6E7545B5A"><gtr:id>2BB30ED9-D4C7-4BF2-AF15-B9F6E7545B5A</gtr:id><gtr:name>Price Waterhouse Coopers</gtr:name><gtr:address><gtr:line1>7 More London Riverside</gtr:line1><gtr:postCode>SE1 2RT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAF838B9-722C-4C83-94D8-6182BE543670"><gtr:id>CAF838B9-722C-4C83-94D8-6182BE543670</gtr:id><gtr:name>Cambridge Reactor Design Ltd</gtr:name><gtr:address><gtr:line1>Unit D2, Brookfield Business Centre</gtr:line1><gtr:line2>Twentypence Rd, Cottenham</gtr:line2><gtr:postCode>CB4 8PS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51336368-4D84-4225-8CF4-FB55E1DA006E"><gtr:id>51336368-4D84-4225-8CF4-FB55E1DA006E</gtr:id><gtr:name>Process Systems Enterprises Ltd</gtr:name><gtr:address><gtr:line1>Head Office</gtr:line1><gtr:line2>6th Floor East</gtr:line2><gtr:line3>26-28 Hammersmith Grove</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W6 7HA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A4C78265-0DA0-48BA-9FDD-357D691643FB"><gtr:id>A4C78265-0DA0-48BA-9FDD-357D691643FB</gtr:id><gtr:name>Encap Drug Delivery</gtr:name><gtr:address><gtr:line1>Units 4, 5 &amp; 6</gtr:line1><gtr:line2>4-6 Oakbank Park Way</gtr:line2><gtr:line3>Mid Calder</gtr:line3><gtr:postCode>EH53 0TH</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3E32B22B-ACAC-468E-A37D-47E5D28813B9"><gtr:id>3E32B22B-ACAC-468E-A37D-47E5D28813B9</gtr:id><gtr:name>Dr Reddy's Laboratories UK Ltd</gtr:name><gtr:address><gtr:line1>410 Cambridge Park</gtr:line1><gtr:line2>Milton Road</gtr:line2><gtr:postCode>CB4 0PE</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B9542CC-D7F0-45DA-A423-16458386EA25"><gtr:id>5B9542CC-D7F0-45DA-A423-16458386EA25</gtr:id><gtr:name>GlaxoSmithKline PLC</gtr:name><gtr:address><gtr:line1>Park Road</gtr:line1><gtr:postCode>SG12 0DP</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0B03E818-F931-4973-B4F6-86CF1F1DDB4C"><gtr:id>0B03E818-F931-4973-B4F6-86CF1F1DDB4C</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:surname>Nordon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0D8ECEF3-26F8-4E14-A212-D768C5AF606B"><gtr:id>0D8ECEF3-26F8-4E14-A212-D768C5AF606B</gtr:id><gtr:firstName>Jagjit</gtr:firstName><gtr:otherNames>Singh</gtr:otherNames><gtr:surname>Srai</gtr:surname><gtr:orcidId>0000-0003-2277-2127</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D875086-CC02-451C-A671-0249871750FC"><gtr:id>3D875086-CC02-451C-A671-0249871750FC</gtr:id><gtr:firstName>Jan</gtr:firstName><gtr:surname>Sefcik</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5728CD9E-C054-4345-8BE1-2541441351C3"><gtr:id>5728CD9E-C054-4345-8BE1-2541441351C3</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Florence</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AF591AAB-4B3F-41AC-B0D4-1DF4D1C73E30"><gtr:id>AF591AAB-4B3F-41AC-B0D4-1DF4D1C73E30</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Rielly</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA959EE6-55F6-4BA0-ADC9-7200AB07E70F"><gtr:id>DA959EE6-55F6-4BA0-ADC9-7200AB07E70F</gtr:id><gtr:firstName>Joop</gtr:firstName><gtr:surname>ter Horst</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5C572566-FAEB-4A37-91BE-5EFD3F434744"><gtr:id>5C572566-FAEB-4A37-91BE-5EFD3F434744</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Roberts</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FEBBC7FC-36DC-4BA1-886D-AE15CFA8DABC"><gtr:id>FEBBC7FC-36DC-4BA1-886D-AE15CFA8DABC</gtr:id><gtr:firstName>Blair</gtr:firstName><gtr:otherNames>Fraser</gtr:otherNames><gtr:surname>Johnston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/05E079FC-4A71-478A-8432-A53536B5E053"><gtr:id>05E079FC-4A71-478A-8432-A53536B5E053</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Crichton</gtr:otherNames><gtr:surname>Wilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3E115165-2E46-4500-A7F1-83C23A29C0A1"><gtr:id>3E115165-2E46-4500-A7F1-83C23A29C0A1</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:surname>Halbert</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/17B36DFB-51CD-4A9A-BF08-BCAE3224B789"><gtr:id>17B36DFB-51CD-4A9A-BF08-BCAE3224B789</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Litster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/696AA5EA-FD85-4352-BE7A-7C11309C0AF8"><gtr:id>696AA5EA-FD85-4352-BE7A-7C11309C0AF8</gtr:id><gtr:firstName>Rachel Marie</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C604EDD6-396E-4526-A6BC-0DBA640E47DF"><gtr:id>C604EDD6-396E-4526-A6BC-0DBA640E47DF</gtr:id><gtr:firstName>Brahim</gtr:firstName><gtr:surname>Benyahia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FA5ACFF5-711E-4992-B88F-9CC8D8885A4A"><gtr:id>FA5ACFF5-711E-4992-B88F-9CC8D8885A4A</gtr:id><gtr:firstName>Sven</gtr:firstName><gtr:otherNames>Lars</gtr:otherNames><gtr:surname>Schroeder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C8870C1F-3106-460F-B065-82D1108B00EF"><gtr:id>C8870C1F-3106-460F-B065-82D1108B00EF</gtr:id><gtr:firstName>Andy</gtr:firstName><gtr:surname>Neely</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FF8846A0-D378-4392-B070-A0B24322D6EB"><gtr:id>FF8846A0-D378-4392-B070-A0B24322D6EB</gtr:id><gtr:firstName>Claire</gtr:firstName><gtr:otherNames>Sandrine</gtr:otherNames><gtr:surname>Adjiman</gtr:surname><gtr:orcidId>0000-0002-4573-7722</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DD56D780-8B2E-451E-A6E1-51714CE4B43C"><gtr:id>DD56D780-8B2E-451E-A6E1-51714CE4B43C</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Price</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FP006965%2F1"><gtr:id>C6736960-E93B-4B11-B219-96D01B088510</gtr:id><gtr:title>Future Continuous Manufacturing and Advanced Crystallisation Research Hub</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/P006965/1</gtr:grantReference><gtr:abstractText>Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate &amp;pound;50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials. 

Changing the way in which these materials are made, from what is called &amp;quot;batch&amp;quot; crystallisation (using large volume tanks) to &amp;quot;continuous&amp;quot; crystallisation (a more dynamic, &amp;quot;flowing&amp;quot; process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK. 

Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed anufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them. 

Our talented team of scientists will use the outstanding capabilities in the award winning &amp;pound;34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain R&amp;amp;D framework'. 

Our vision will be translated from research into industry through partnership and co-investment of &amp;pound;31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing.</gtr:abstractText><gtr:potentialImpactText>The CMAC Future Manufacturing Hub team actively engage and collaborate with a wide range of research beneficiaries: leading pharmaceutical companies (e.g. AZ, GSK, Bayer, Pfizer, Lilly); companies in the process industries (e.g. Mars, AB Sugar, Syngenta, Croda); technology and supply chain companies (e.g. Siemens and 15 SMEs). It has a vibrant innovation landscape with partners including; HVM Catapult (CPI); the National Formulation Centre; medical charities (e.g. CRUK), Medicines Manufacturing Industry Partnership (MMIP) of the UK pharma manufacturing industry; Chemical Growth Partnership; International academic partners (Rutgers, Graz, Singapore) through the newly formed International Institute of Advanced Pharmaceutical Manufacturing. This strong, active and influential network of collaborators, stakeholders and business leaders (contributing &amp;pound;31.2m to translate the research into impact), maximises the potential to achieve the Hub vision will create substantial associated impact and benefits including:
1. Economic Impact: contributing to the UK economy by increasing the competitiveness of companies across the &amp;pound;50Bn Pharmaceutical and Chemicals sector. The Hub programme will impact on business innovative capacity and revenues by giving industry access to a 'particle production toolbox' which will increase competitiveness by enabling flexibility of product supply delivered through integrated multi-step continuous manufacturing processes. The Hub will accelerate development and scale up of products with improved costs, energy and material usage, delivering regeneration and economic development opportunities through creation and growth of new companies and jobs through the exploitation and commercialisation of novel processing and platform formulation technologies (potential licensing, spin-out formation) attracting direct inward R&amp;amp;D investment investments from global businesses.
2. Wider Societal Impacts: delivering improvements to life quality and health &amp;amp; webeing through improvements to the speed and agility of drug development, manufacture and supply required to meet current unmet customer and patient needs and future demand; availability of a wider range of effective, safe and economically viable products will impact on health across the population. Through smaller plant footprint and reduced energy consumption, continuous manufacturing will deliver lower production costs and significant positive environmental impacts. Engaging with policy-makers and influencing future regulatory frameworks will be a key activity to realise the full potential of these transformative innovations in highly regulated sectors. The manufacturing technology developments will also impact internationally - small modular reconfigurable manufacturing capability with automated, intelligent control has the potential to enable distributed manufacture with units positioned close to the point of need, tackling global priority problems; opportunities for anti-malarial or anti-retroviral products at low cost in developing economies for local distribution to patients will improve access to safe and effective healthcare.
3. Academic Impacts: an interdisciplinary approach to developing new and innovative methodologies and technologies will deliver worldwide academic opportunities in addressing the challenges facing global pharmaceutical and chemicals industries. A unique focus on manufacturing technology and connectivity across multiple stakeholders will enhance the profile of manufacturing research in key sectors of the UK economy, increasing research activity and capacity. Through training highly skilled researchers and attracting talent, a pipeline of knowledge and skilled people will be created for businesses, international collaboration, engagement and research impact (e.g. through co-authored research papers) and new opportunities for UK researchers to obtain international experience via researcher exchanges through CMACs global network.</gtr:potentialImpactText><gtr:fund><gtr:end>2023-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2017-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>10330543</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5DBD1C81-9029-4054-B75A-B5B5310ACE07</gtr:id><gtr:title>Convergent Innovation in Emerging Healthcare Technology Ecosystems: Addressing Complexity and Integration</gtr:title><gtr:parentPublicationTitle>Technology Innovation Management Review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef25d9912e931efe48097dffc335b4ef"><gtr:id>ef25d9912e931efe48097dffc335b4ef</gtr:id><gtr:otherNames>Phillips M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a3bdaf1d4b489.16296797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAFC2A4D-CB51-4238-8FE0-5C041D17B50C</gtr:id><gtr:title>Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice: September 26-27, 2016, International Symposium on the Continuous Manufacturing of Pharmaceuticals.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/297875bfe6929d722578528df21fb814"><gtr:id>297875bfe6929d722578528df21fb814</gtr:id><gtr:otherNames>Nasr MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn><gtr:outcomeId>5a3bdaf12877d6.64578522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DF91573-0F31-4A4A-AB4A-0C9DBE6985FE</gtr:id><gtr:title>Scaling of continuous twin screw wet granulation</gtr:title><gtr:parentPublicationTitle>AIChE Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc30c9755ce96d2262f0d8a1211cc52f"><gtr:id>cc30c9755ce96d2262f0d8a1211cc52f</gtr:id><gtr:otherNames>Osorio J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0001-1541</gtr:issn><gtr:outcomeId>5a816b70b3aab6.62774625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F0FB1D-B72E-409A-9D28-CBA3A573EF02</gtr:id><gtr:title>Spray Drying as a Reliable Route to Produce Metastable Carbamazepine Form IV.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01ba28454b176119d75cb8dbeec4d678"><gtr:id>01ba28454b176119d75cb8dbeec4d678</gtr:id><gtr:otherNames>Halliwell RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn><gtr:outcomeId>5a3bdaf1048ba5.23955643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26411F17-ACA9-465C-9065-9722B39A97E8</gtr:id><gtr:title>Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33c42a6346826475427f1cd0294980f3"><gtr:id>33c42a6346826475427f1cd0294980f3</gtr:id><gtr:otherNames>Perrier J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0928-0987</gtr:issn><gtr:outcomeId>5a8169b2cdc8b0.96628416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A8042B4-FABA-429D-B1BE-02821D914E36</gtr:id><gtr:title>Direct Observation of Templated Two-Step Nucleation Mechanism during Olanzapine Hydrate Formation</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6ba1c9f4551f164545652ed22643db1"><gtr:id>b6ba1c9f4551f164545652ed22643db1</gtr:id><gtr:otherNames>Warzecha M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a3bdaf14a90b7.92203892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9A2ADDA-ABD1-4AAB-B47E-9EC69C7DB1B4</gtr:id><gtr:title>Particle design via spherical agglomeration: A critical review of controlling parameters, rate processes and modelling</gtr:title><gtr:parentPublicationTitle>Powder Technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af44156afdbcc0c5ad1dfdb3058067e5"><gtr:id>af44156afdbcc0c5ad1dfdb3058067e5</gtr:id><gtr:otherNames>Pitt K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a3bdaf0ac0753.15678228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8CDCB33-0B1A-4317-B164-DC27DF3E6233</gtr:id><gtr:title>Pharmaceutical supply chain models: A synthesis from a systems view of operations research</gtr:title><gtr:parentPublicationTitle>Operations Research Perspectives</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fae8529f720952c68f081091c6bde12"><gtr:id>3fae8529f720952c68f081091c6bde12</gtr:id><gtr:otherNames>Settanni E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a352c591d08f5.57127862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EE2DFE6-FC55-46E3-9910-9C92CC685AC4</gtr:id><gtr:title>Degradation Behavior of Silk Nanoparticles-Enzyme Responsiveness</gtr:title><gtr:parentPublicationTitle>ACS Biomaterials Science &amp; Engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f665e873acf616ffa68db45c951ef88"><gtr:id>1f665e873acf616ffa68db45c951ef88</gtr:id><gtr:otherNames>Wongpinyochit T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a995ab2cc3881.60422216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ABB2BC8-AD81-4689-BE77-18771E3DD03E</gtr:id><gtr:title>The Effect of Ultrasound on the Crystallisation of Paracetamol in the Presence of Structurally Similar Impurities</gtr:title><gtr:parentPublicationTitle>Crystals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18b783a025bc2fdd6d6e89b3dc8bcbb4"><gtr:id>18b783a025bc2fdd6d6e89b3dc8bcbb4</gtr:id><gtr:otherNames>Nguyen T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a3bdaf2058164.94440955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59CFC8AD-9A2E-47DA-BF62-893C9AA43791</gtr:id><gtr:title>Self-assembly of ultra-small micelles from amphiphilic lipopeptoids.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d5176a5c032fefef6e43548814c6df"><gtr:id>11d5176a5c032fefef6e43548814c6df</gtr:id><gtr:otherNames>Lau KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5a3bdaf1b24345.45493063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EA6796B-4179-40B4-B95C-ACE2A8933B05</gtr:id><gtr:title>Dual Level Statistical Investigation of Equilibrium Solubility in Simulated Fasted and Fed Intestinal Fluid.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a910be11bd5df0bbf1f36319863f5811"><gtr:id>a910be11bd5df0bbf1f36319863f5811</gtr:id><gtr:otherNames>Ainousah BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>5a816a0a2d6d32.54955260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7167022E-C61F-445D-98EB-C60C87B90E26</gtr:id><gtr:title>Mesoscopic Solute-Rich Clusters in Olanzapine Solutions</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6ba1c9f4551f164545652ed22643db1"><gtr:id>b6ba1c9f4551f164545652ed22643db1</gtr:id><gtr:otherNames>Warzecha M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a3bdaf174f048.65741612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C38B450-24E0-4699-BBD8-435B4CC6B05E</gtr:id><gtr:title>Rapid Continuous Antisolvent Crystallization of Multicomponent Systems</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0630e40ace960faa3401e59b48ba350"><gtr:id>e0630e40ace960faa3401e59b48ba350</gtr:id><gtr:otherNames>Raza S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a37f4ebe095e4.50460470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC0C9920-BFDA-4E85-8D00-22850597A83E</gtr:id><gtr:title>Influence of Physiological Gastrointestinal Surfactant Ratio on the Equilibrium Solubility of BCS Class II Drugs Investigated Using a Four Component Mixture Design.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bf1ecd4c4c7b837a4d6237fe9fed466"><gtr:id>2bf1ecd4c4c7b837a4d6237fe9fed466</gtr:id><gtr:otherNames>Zhou Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>5a8169dd24ef80.95610782</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/P006965/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>FA25733D-A456-4A1B-9D5C-7119577368D9</gtr:id><gtr:percentage>70</gtr:percentage><gtr:text>Manufacturing</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9767B5B6-94F7-4DF6-8415-C15629D67796</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Complex fluids &amp; soft solids</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>2E2E80C2-8D14-44CE-A971-37A9ACC4B244</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Manufact. Enterprise Ops&amp; Mgmt</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>ABBD3B7F-5022-4513-82D6-5414B965FAB3</gtr:id><gtr:percentage>55</gtr:percentage><gtr:text>Manufacturing Machine &amp; Plant</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>04DC091E-A791-4572-A9B7-E327BB0A3EB8</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Particle Technology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>